Overview
Pain is a multidimensional sensory and emotional experience that is important for our survival, but once pain becomes chronic it is no longer beneficial and, instead, becomes a disorder in and of itself. Chronic pain remains one of our nation’s most significant healthcare problems due to a limited understanding of the underlying genetic and environmental factors. There are three main objectives of our lab’s research in this area:
- To determine the factors that put some people, but not others, at risk for maladaptive chronic pain conditions. To achieve this objective, we study genetic, biological, and environmental factors associated with the initial onset of pain as well as its severity and duration. In addition, we are beginning to study factors associated with patient-centered outcomes, which may have the power to predict optimal management strategies for different individuals.
- To elucidate the mechanism(s) whereby genetic, biological, and environmental factors drive chronic pain. To achieve this objective, we integrate molecular genetics, animal models, and clinical epidemiologic measures in order to reveal pathogenic processes that are unique to as well as common across a particular condition or individual(s). This line of inquiry will provide novel targets for the development of individualized therapeutics for the management of chronic pain.
- To improve pharmacologic management of pain. To achieve this objective, we conduct pre-clinical studies to test the efficacy of new compounds and to optimize the efficacy of existing compounds in patient-relevant animal models.
Current Duke Appointments & Affiliations
Associate Professor in Anesthesiology
·
2019 - Present
Anesthesiology,
Clinical Science Departments
Associate Professor in Pharmacology and Cancer Biology
·
2017 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Recent Scholarly Works
LPA/LPAR signaling drives temporomandibular disorders-like pain through regulating the expression and sensitization of PIEZO2.
Journal article Sci Adv · July 24, 2026 Temporomandibular disorders (TMD) pain is the most common orofacial pain with limited effective treatments. Here, we observed elevated lysophosphatidic acid (LPA), a bioactive lipid, in blood, trigeminal ganglion (TG), and peri-temporomandibular joint (TMJ ... Full text Open Access Link to item CiteAssociation of Preoperative Cerebrospinal Fluid Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand With 1-Year Postsurgical Pain Severity in Older Adults: A Trial Secondary Analysis.
Journal article Anesth Analg · June 16, 2026 Full text Link to item CiteIntroduction to the special issue on epigenetic regulation of chronic pain.
Journal article Pain Rep · April 2026 This Special Issue features 6 articles from leaders in the field that elucidate novel epigenetic mechanisms regulating nociception, inflammation, responses to pharmacologic and integrative therapies, and pain disparities among racial/ethnic groups. Togethe ... Full text Link to item CiteRecent Grants
Defining the role of peripheral Adrb3 in chronic pain and inflammation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2026 - 2031Integrated Training in Anesthesiology Research
Inst. Training Prgm or CMEMentor · Awarded by National Institute of General Medical Sciences · 1996 - 2031Pharmacological Sciences Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030View All Grants
Education
University of Georgia ·
2003
Ph.D.